- Harmony Biosciences (NASDAQ: HRMY) specializes in developing treatments for central nervous system disorders, with its flagship product WAKIX (pitolisant) positioned as a leading non-scheduled treatment for narcolepsy, achieving over $868 million in net revenue in 2025 and projected to exceed $1 billion in 2026.
- In the past year, Harmony received FDA approval for WAKIX to treat cataplexy in pediatric narcolepsy patients aged 6 and older and expanded its commercial organization by 20% to support growth initiatives.
- The company has settled with six of seven ANDA filers to extend WAKIX's market exclusivity until September 2029, enhancing its competitive position in the narcolepsy treatment market.
- Harmony's ideal buyers are healthcare providers treating narcolepsy, as they seek effective, non-scheduled medications for patients, and the company's recent approvals and pipeline developments present timely opportunities for sales engagement.
Sales and Support is the largest group with 88 employees (about 37% of the company). Finance and Administration has 28 employees, while Operations and Marketing & Product each have 21. Business Management counts 19, Healthcare 17, and Engineering 12. Risk, Safety, and Compliance has 9 employees, Human Resources has 7, and 14 employees are categorized as Other. Across teams, the organization reports 24 new hires and 10 departures.
The workforce is broadly distributed, with 147 employees in Other locations (about 62% of the total). Among named hubs, Philadelphia, PA has 41 employees, followed by Chicago, IL with 13 and Plymouth Meeting, PA with 9. Additional presence includes New York, NY (6), Washington, DC (5), West Chester, PA (5), Atlanta, GA (4), Boston, MA (3), and Houston, TX (3). Pennsylvania representation spans multiple locations, including Philadelphia, Plymouth Meeting, and West Chester.
